# Janssen Pharmaceutica N.V., Belgium trials: 58 (2026)

ClinicalTrials.gov lists 58 trials with Janssen Pharmaceutica N.V., Belgium as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Janssen Pharmaceutica N.V., Belgium: 58 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-pharmaceutica-n-v-belgium

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 58
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 58, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 9, 2024 | NCT06544616 | A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Janssen Pharmaceutica N.V., Belgium | Phase 2 | Active not recruiting | Alzheimer Disease | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06544616) |
| January 31, 2023 | NCT05706753 | A Study of Milvexian in Healthy Adult Females | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Completed | Healthy Female | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05706753) |
| September 23, 2022 | NCT05552196 | A Study of Ponesimod in Healthy Adult Participants | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05552196) |
| September 22, 2022 | NCT05550519 | A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment | Janssen Pharmaceutica N.V., Belgium | Early phase 1 | Withdrawn | Hepatitis B, Chronic | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05550519) |
| April 14, 2022 | NCT05328297 | A Study of JNJ-55308942 in the Treatment of Bipolar Depression | Janssen Pharmaceutica N.V., Belgium | Phase 2 | Completed | Bipolar Disorder | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05328297) |
| December 16, 2021 | NCT05160584 | A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma | Janssen Pharmaceutica N.V., Belgium | Observational | Active not recruiting | Relapsed/Refractory Multiple Myeloma | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05160584) |
| September 20, 2021 | NCT05049798 | A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice | Janssen Pharmaceutica N.V., Belgium | Observational | Active not recruiting | Arthritis, Psoriatic | 1,314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05049798) |
| September 28, 2020 | NCT04566926 | A Study of JNJ-64140284 in Healthy Male Participants | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Terminated | Healthy | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04566926) |
| September 21, 2020 | NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | Janssen Pharmaceutica N.V., Belgium | Phase 3 | Active not recruiting | Prostatic Neoplasms | 691 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04557059) |
| June 11, 2020 | NCT04426357 | A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult... | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Terminated | Renal Impairment | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04426357) |
| May 14, 2020 | NCT04388501 | A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Completed | Healthy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04388501) |
| May 8, 2020 | NCT04380961 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | Janssen Pharmaceutica N.V., Belgium | Phase 2 | Completed | Critical Confirmed Coronavirus Disease (COVID)-19 | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04380961) |
| January 22, 2020 | NCT04236453 | A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat... | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Terminated | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04236453) |
| July 5, 2019 | NCT04006704 | Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC)... | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Completed | HIV-1 | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04006704) |
| March 20, 2019 | NCT03882255 | A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Completed | Healthy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03882255) |
| January 8, 2019 | NCT03796858 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha... | Janssen Pharmaceutica N.V., Belgium | Phase 3 | Completed | Arthritis, Psoriatic | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03796858) |
| June 16, 2017 | NCT03189498 | A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of... | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Completed | Renal Insufficiency | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03189498) |
| December 30, 2016 | NCT03006198 | Tracking Biologics Along the Silk Road | Janssen Pharmaceutica N.V., Belgium | Observational | Completed | Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03006198) |
| June 27, 2016 | NCT02813408 | A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes... | Janssen Pharmaceutica N.V., Belgium | Observational | Completed | Prostatic Neoplasms | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02813408) |
| June 1, 2016 | NCT02786381 | Idylla IFV-RSV Panel Clinical Testing | Janssen Pharmaceutica N.V., Belgium | Observational | Completed | Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02786381) |
| December 11, 2015 | NCT02627768 | A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis | Janssen Pharmaceutica N.V., Belgium | Observational | Completed | Psoriatic Arthritis | 991 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02627768) |
| August 26, 2015 | NCT02532842 | Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate | Janssen Pharmaceutica N.V., Belgium | Observational | Completed | Schizophrenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02532842) |
| September 10, 2014 | NCT02236637 | A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care | Janssen Pharmaceutica N.V., Belgium | Observational | Completed | Prostate Cancer | 3,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02236637) |
| February 19, 2014 | NCT02065739 | A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants | Janssen Pharmaceutica N.V., Belgium | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02065739) |
| November 8, 2013 | NCT01980290 | Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C | Janssen Pharmaceutica N.V., Belgium | Observational | Completed | Hepatitis, Chronic | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01980290) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 4 |
| Phase 1 | 12 |
| Phase 2 | 4 |
| Phase 3 | 16 |
| Phase 4 | 8 |
| Observational | 14 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 49 |
| Active not recruiting | 4 |
| Terminated | 4 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 11 |
| Psychotic Disorders | 6 |
| Alzheimer Disease | 5 |
| Prostatic Neoplasms | 4 |
| Attention Deficit Disorder with Hyperactivity | 3 |
| Dementia | 3 |
| Arthritis, Psoriatic | 3 |
| Multiple Myeloma | 3 |
| Bipolar Disorder | 3 |
| Cognition Disorders | 3 |
| Arthritis | 3 |
| Conduct Disorder | 2 |
| Attention Deficit and Disruptive Behavior Disorders | 2 |
| Oppositional Defiant Disorder | 2 |
| Renal Insufficiency | 2 |
| Migraine Disorders | 2 |
| Headache | 2 |
| Osteoarthritis | 2 |
| Kidney Failure, Chronic | 1 |
| Hypertrophy, Left Ventricular | 1 |
| Hepatitis B, Chronic | 1 |
| Nervous System Diseases | 1 |
| Mental Disorders | 1 |
| Brain Diseases | 1 |
| Memory Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Armenian restaurants in the United States](https://specstream.ai/data/businesses/armenian-restaurants/united-states)
- [Vegetarian restaurants in the United States](https://specstream.ai/data/businesses/vegetarian-restaurants/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
